PDGFR-α Biomarker Detection for Metastatic Thyroid Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for identifying and treating metastatic papillary thyroid cancer (PTC) lack effective biomarkers for predicting lymphatic metastasis, leading to increased morbidity and recurrence rates due to inadequate prediction of metastatic potential.
Innovation Solution
A method involving an analyte binding assay to detect platelet-derived growth factor receptor α (PDGFR-α) in tumor samples, using reagents that specifically bind to PDGFR-α, and administering targeted treatments such as tyrosine kinase inhibitors when elevated PDGFR-α levels are detected.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If fine needle aspiration (FNA) biopsy is used to assess thyroid nodules, then cancer can be distinguished from benign disease in approximately 65% of cases, but no information is provided on the metastatic potential of thyroid malignancy
Solution Approach 1:
The assessment process is segmented into two distinct components: (1) FNA biopsy for initial cancer detection, and (2) PDGFR-α immunohistochemical staining for metastatic potential evaluation. This segmentation allows each test to optimize for its specific purpose without compromising the other.
Solution Approach 2:
PDGFR-α expression serves as an intermediary biomarker that bridges the gap between initial cancer diagnosis and metastatic risk assessment. The immunohistochemical detection of PDGFR-α provides indirect information about metastatic potential without requiring direct observation of metastatic spread.
2Reliability
If patients with metastatic or recurrent PTC undergo multiple surgical resections and radioactive iodine ablative treatments, then disease control may be achieved, but associated increased morbidity occurs
Solution Approach 1:
PDGFR-α testing is performed preliminarily on the initial tumor sample to predict metastatic risk before definitive treatment decisions are made. This preliminary information allows clinicians to plan more aggressive initial treatments for high-risk patients, potentially preventing future recurrences and reducing the need for repeated interventions.
Solution Approach 2:
The PDGFR-α expression level provides feedback about the biological aggressiveness of the tumor, which then guides treatment intensity. High PDGFR-α expression triggers more aggressive treatment protocols, while low expression allows for conservative management, creating a feedback loop that tailors treatment to individual patient risk.
3Measurement precision
If genetic testing regimes for RET/PTC, BRAF, and RAS mutations are utilized, then diagnostic accuracy is improved, but these tests are utilized selectively in only a few high-volume centers
Solution Approach 1:
The PDGFR-α immunohistochemical assay uses standard pathology laboratory reagents and procedures that are widely available in routine diagnostic settings. The test employs conventional immunohistochemistry techniques with commercially available antibodies, making it accessible to any pathology laboratory without requiring specialized molecular genetics facilities.
Solution Approach 2:
The PDGFR-α test serves multiple functions: it assesses metastatic potential, guides treatment decisions, and provides prognostic information. This multi-functionality consolidates what would otherwise require multiple separate specialized tests into a single universally applicable assay.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the identification of subjects with increased likelihood of metastatic PTC and guides targeted therapies, potentially reducing recurrence and improving quality of life by predicting metastatic potential and tailoring treatment strategies.
Implementation Method 1
contacting a processed sample, said processed sample obtained from a subject with thyroid cancer, with a reagent to form a complex between the reagent and a biomarker present in the sample
Data Source
AI summary
Provided herein are methods for identifying a subject with an increased likelihood of developing or having metastatic papillary thyroid cancer (PTC), or a subject with an increased likelihood of developing or having recurrent PTC, and the treatment of such a subject.